Olaparib

Major

Olaparib Nefazodone Increased olaparib exposure Details Olaparib Nelfinavir Viracept Increased olaparib exposure Details Olaparib Netupitant Increased olaparib exposure Details Olaparib Nilotinib Increased olaparib exposure Details Olaparib Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Olaparib Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Olaparib Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Olaparib Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Olaparib Phenobarbital Fidoquel Decreased olaparib exposure and efficacy Details Olaparib Phenytoin Dilantin Decreased olaparib exposure and efficacy Details Olaparib Pimozide Increased pimozide exposure Details Olaparib Posaconazole Noxafil Increased olaparib exposure Details Olaparib Primidone Mysoline Decreased olaparib exposure and efficacy Details Olaparib Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Olaparib Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Olaparib Repotrectinib Augtyro Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Olaparib Ribociclib Kisqali Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Olaparib Rifampin Rifadin Decreased olaparib exposure and efficacy Details Olaparib Ritonavir Norvir Increased olaparib exposure Details Olaparib Roflumilast Daliresp Increased roflumilast exposure and an increased risk of roflumilast-related adverse events Details Olaparib Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Olaparib Saquinavir Increased olaparib exposure Details Olaparib Selpercatinib Retevmo Increased substrate exposure and an increased risk for adverse effects Details Olaparib Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Olaparib Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Olaparib St John's Wort Decreased olaparib exposure and efficacy Details Olaparib Suzetrigine Journavx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Olaparib Taurursodiol Decreased exposure of the CYP3A4 substrate Details Olaparib Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Olaparib Telaprevir Increased olaparib exposure Details Olaparib Telithromycin Increased olaparib exposure Details Olaparib Ticagrelor Brilinta Increased olaparib exposure Details Olaparib Tipranavir Aptivus Increased olaparib exposure Details Olaparib Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Olaparib Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Olaparib Tramadol ConZip Increased traMADol exposure and an increased risk of seizures, serotonin syndrome and opioid toxicity Details Olaparib Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Olaparib Tucatinib Tukysa Increased exposure to CYP3A substrate and risk of toxicity Details Olaparib Verapamil Calan Increased olaparib exposure Details Olaparib Vonoprazan Voquezna Increased CYP3A substrates exposure Details